TapImmune, Inc. (TPIV) Reaches $3.61 After 7.00% Up Move; Cogint (COGT) Sellers Increased By 10.87% Their Shorts

January 14, 2018 - By Vivian Park

Cogint Incorporated (NASDAQ:COGT) had an increase of 10.87% in short interest. COGT’s SI was 2.33 million shares in January as released by FINRA. Its up 10.87% from 2.10 million shares previously. With 302,300 avg volume, 8 days are for Cogint Incorporated (NASDAQ:COGT)’s short sellers to cover COGT’s short positions. The SI to Cogint Incorporated’s float is 11.59%. The stock increased 1.03% or $0.05 during the last trading session, reaching $4.9. About 1.25 million shares traded or 123.65% up from the average. Cogint, Inc. (NASDAQ:COGT) has risen 5.58% since January 14, 2017 and is uptrending. It has underperformed by 11.12% the S&P500.

The stock of TapImmune, Inc. (NASDAQ:TPIV) is a huge mover today! The stock increased 4.03% or $0.14 during the last trading session, reaching $3.61. About 53,359 shares traded or 42.76% up from the average. TapImmune, Inc. (NASDAQ:TPIV) has declined 49.91% since January 14, 2017 and is downtrending. It has underperformed by 66.61% the S&P500.The move comes after 5 months positive chart setup for the $38.29 million company. It was reported on Jan, 14 by Barchart.com. We have $3.86 PT which if reached, will make NASDAQ:TPIV worth $2.68 million more.

Cogint, Inc., a data and analytics company, provides cloud information and performance marketing solutions to enterprises in various industries in the United States. The company has market cap of $292.42 million. It operates in two divisions, Information Services and Performance Marketing. It currently has negative earnings. The Information Services segment provides solutions to organizations in the risk management and consumer marketing industries.

TapImmune, Inc., a clinical-stage immuno-oncology company, develops peptide and gene immunotherapeutics and vaccines for the treatment of cancer and metastatic disease. The company has market cap of $38.29 million. It specializes in the development of immunotherapies targeting womenÂ’s cancers advancing multiple Phase II and Phase Ib/II clinical studies for the treatment of ovarian and breast cancers. It currently has negative earnings. The companyÂ’s peptide-or nucleic acid immunotherapeutic products comprise one or multiple naturally processed epitopes designed to comprehensively stimulate a patientÂ’s killer T cells and helper T cells, and to restore or further augment antigen presentation by using proprietary nucleic acid expression systems.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts

Twitter Auto Publish Powered By : XYZScripts.com